medRxiv
July 10, 2026
Lada Kohoutová, Jevita Potheegadoo, Léa F Duong Phan Thanh et al.
Hallucinations in Parkinson's disease, from minor to structured, are linked to changes in brain connectivity and cognitive decline. Non-demented patients with minor or structured hallucinations share a common pattern of resting-state functional connectivity that is absent in patients without hallucinations. This pattern involves connections between subcortical areas and visual, attention, and default mode networks, as well as within-cerebellar and within-subcortical connectivity. The pattern is equally expressed in both hallucination groups and is associated with impairments in attention and executive function, as well as increased sensitivity to an experimental procedure that induces presence hallucinations. The findings suggest that altered subcortical-cortical connectivity underlies hallucinations even in their early, minor forms.
medRxiv
July 8, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Yonatan Sanz Perl et al.
In people with major depressive disorder, mindfulness-based cognitive therapy (MBCT) plus treatment as usual, compared to treatment as usual alone, alters whole-brain dynamics in ways that may reduce rumination. Using a novel method called complex harmonics decomposition on fMRI data from 80 patients, the study identified low-dimensional spatiotemporal manifolds that capture both local and long-range brain interactions. After MBCT, during rumination, brain regions involved in bodily and interoceptive processing became more consistently integrated across these manifolds. The latent configurations shifted with clinical and behavioral improvements, and the brain showed greater flexibility within the reduced space. These changes may reflect reduced 'stickiness' of ruminative thinking patterns following mindfulness training.
medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Combining intranasal oxytocin with mindfulness-based group therapy may improve negative symptoms in schizophrenia spectrum disorders. In a pilot study, 47 participants received either oxytocin or placebo before four therapy sessions. Only the oxytocin group showed significant reductions in negative symptoms from baseline to post-intervention and at a 4-week follow-up, with small between-group effects favoring oxytocin at follow-up. No serious adverse events occurred. The findings support further large-scale trials.
medRxiv
June 24, 2026
Dhruv Adhia, Deepali Raithatha, Arron Ferguson et al.
A mobile breathwork system called Vayu, which uses an Apple Watch and iPhone app, delivers slow breathing guided by wrist-based haptic cues, adapts pacing to heart rate variability (HRV), and includes reflective journaling. In a 4–6-week pilot with 199 adults across Canada, the United States, and India, participants did daily 5–10-minute sessions. Average adherence was 4.1 sessions per week, with 71% of active users doing at least 3 sessions weekly. By week four, perceived stress decreased by 2.5 points on the PSS-10, resting heart rate fell by 7.4 bpm, and HRV increased by a median of 28.6% from baseline, along with mood improvements. No adverse events occurred. The findings suggest the system is effective and well-tolerated.
medRxiv
June 23, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Henricus G. Ruhé et al.
In people with major depressive disorder, mindfulness-based cognitive therapy (MBCT) plus treatment as usual, compared to treatment as usual alone, increased the hierarchical organization of brain activity during rumination but not at rest. Greater hierarchy—meaning more directional information flow and less recurrent looping—was linked to improvements in clinical and behavioral outcomes. This shift away from self-reinforcing negative mental loops toward more differentiated cognitive and bodily cycles may help explain how MBCT interrupts ruminative thought patterns. Hierarchical brain dynamics could serve as a treatment-sensitive marker and potential mechanism of therapeutic change in MBCT for depression.
medRxiv
June 22, 2026
Roi Basch, Maya Cohen, Leehe Peled-Avron
Serotonin-boosting treatments, such as SSRIs and psychedelics, consistently reduce repetitive negative thoughts like rumination, worry, and obsessions, but do not reliably improve performance on lab tests of cognitive flexibility. A meta-analysis of 2,030 participants across 45 effect sizes found that acute tryptophan depletion did not impair cognitive flexibility, and serotonin elevation did not enhance it. However, serotonin elevation produced a medium-to-large reduction in pathological perseverative thinking. The effect was stronger in samples with more female participants, and psilocybin showed a marginally larger reduction than SSRIs. The findings suggest serotonin's role in emotional and cognitive rigidity is distinct from its effects on objective executive function.
medRxiv
June 1, 2026
Erica J. Li, Basmah Mosharraf, Hiba Ali et al.
In a survey of 295 adults with musculoskeletal pain attending a hospital orthopaedic clinic, most perceived psilocybin as moderately to highly effective for pain (76%) and expressed moderate-to-high willingness to try microdoses (58%) or macrodoses (53%) of psilocybin for pain. Prior non-therapeutic psychedelic use was the strongest predictor of willingness to try a macrodose (B=3.16) or microdose (B=2.82), while pain severity had a small but significant effect. Only 3% had discussed psychedelics with a healthcare provider, and health risks were the primary concern (33%). The findings suggest neutral-to-positive perceptions, with gaps in patient knowledge and health concerns as key barriers to address in future trials.
medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
Under Oregon's regulated psilocybin program, adults who consumed an average of 27.8 mg of psilocybin showed significant improvements in depression, anxiety, and well-being 30 days after a session, including those concurrently using psychiatric medication. Of 88 participants (median age 43, 52% male, 64.8% with prior psychedelic experience), two reported symptoms of hallucinogen persisting perception disorder one day after the session, but none at 30 days. The findings suggest that legal psilocybin services can produce clinically meaningful mental health benefits.
medRxiv
February 17, 2026
Constantin Weberpals, A. Specht, Natasja Bonde Andersen et al.
Type 1 narcolepsy (NT1) involves the loss of hypocretin/orexin transmission, causing daytime sleepiness and abnormal mixing of REM sleep with wakefulness, leading to cataplexy, sleep paralysis, and dream-like hallucinations. Using deep learning of nocturnal sleep polysomnography signals (EEG, EMG, EOG), the study found that NT1 patients show abnormally short wake-to-REM transitions and mixing of wake, N1, and REM sleep stages. This mixing fluctuated across cortical locations, strongest in frontal and central regions, particularly the left hemisphere. The strongest discriminator was N1-REM mixing across central electrodes, with 4.3-fold higher dissociation in NT1 patients (Cohen’s d = 0.61). Local dissociations correlated with CSF orexin/hypocretin levels and MSLT severity. Hypnagogic hallucinations correlated with occipital dissociations, aligning with visual content. Orexin deficiency likely destabilizes REM sleep organization across cortical areas.
medRxiv
December 1, 2025
Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al.
preprint
In a real-world clinical setting, a single dose of LSD (100 µg) or psilocybin (25 mg) combined with psychotherapy significantly reduced depression and anxiety symptoms in 115 adults with treatment-resistant disorders. Symptoms were measured one to three months after treatment, with no serious adverse events. Patients also showed reduced rumination, self-blame, and catastrophizing, along with increased positive refocusing and reappraisal. Both substances produced comparable clinical benefits despite different subjective effect profiles. The findings suggest that psychedelic-assisted psychotherapy is feasible and effective in routine specialized care.
medRxiv
November 17, 2025
Georgia Ioakimidis-Macdougall, John Gardner, Paul Liknaitzky
preprint
A single 25 mg dose of psilocybin, given with psychological support in a clinical setting, helped 14 mental health professionals develop a greater embodied understanding of therapeutic principles and processes. Participants reported increases in empathy, attunement, and emotion regulation—qualities that underpin therapeutic alliance and promote trust and safety. While no harms were reported, participants noted two potential risks: the experience could feel destabilizing, and therapists might project their own experience onto clients, narrowing interpretative range. Participants indicated that such training is necessary but not sufficient for high-quality psychedelic-assisted therapy. Findings support including an optional psychedelic experiential component for clinicians with prior training and reflective capacity.
medRxiv
October 22, 2025
Matthew A Aldridge, Nanda Cara, Alan Simpson et al.
preprint
Second-generation mindfulness-based interventions (SG-MBIs) extend typical mindfulness programs by grounding them in Buddhist epistemology and pedagogy. A scoping review of 16 publications describing 11 unique SG-MBIs, involving 649 university students, found these interventions safe and potentially effective for holistic health promotion. Most studies were in high-income settings with homogeneous samples, narrow psychological outcome focus, and expert-led models. No studies integrated traditional healing systems or assessed physical, social, or spiritual well-being, and tailoring was absent. The Buddhist grounding suggests relevance for culturally congruent interventions in Buddhist-majority low- and middle-income countries, where future research should prioritize collaboration with local specialists.
medRxiv
September 12, 2025
Bryce A. Keating, David R. Vago, Kilian Hett et al.
preprint
Focused attention (FA) meditation reduces regurgitant cerebrospinal fluid (CSF) flow through the cerebral aqueduct and increases low-frequency CSF fluctuations near the skull base, directionally opposite to patterns seen in aging and neurodegeneration and similar to sleep-related CSF dynamics. In 23 adept meditators, absolute aqueduct CSF flow decreased from 4.60±2.27 mL/min during mind wandering to 4.17±2.10 mL/min during FA meditation, driven by reduced cranially-directed regurgitant velocity. No changes occurred in meditation-naïve control groups. The findings suggest mindfulness meditation may be a non-pharmacological waking state that modulates neurofluid circulation in a manner consistent with sleep and contrary to aging-related decline.
medRxiv
August 28, 2025
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
preprint
An international online study of 759 people examined how psychedelic drug use affects cognitive performance and mental health in the short and long term. Participants completed tasks measuring working memory, selective attention, and visual/spatial perception, plus questionnaires on mental health and quality of life. Recent users showed significantly lower accuracy on all cognitive tasks and reported more depressive and dissociative symptoms. Lifetime users had the highest task accuracy without slower reaction times, and their use was not linked to long-term cognitive decline. However, lifetime users scored lower on psychological and social quality of life domains, suggesting possible long-term psychosocial effects.
medRxiv
August 19, 2025
Jun Takezawa, Sinong Geng, Masahiro Fujino et al.
preprint
An observational study using smartwatches and smartphone surveys tracked 90 people for three weeks: 19 regular meditators, 32 recreational runners, and 39 controls with no regular exercise or meditation. Although meditators reported lower stress than controls on questionnaires, their overall heart rate variability (HRV) in daily life was not higher. However, during actual meditation sessions, HRV increased by about 4.7 milliseconds, and this effect lasted at least 30 minutes afterward. In contrast, runners showed both lower stress and higher daily HRV than controls. Across all groups, higher momentary stress was linked to a small concurrent drop in HRV. The findings suggest meditation may offer a way to temporarily boost HRV, which could contribute to stress reduction, but more controlled research is needed.
medRxiv
August 16, 2025
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
preprint
Psilocybin-assisted therapy produces substantial reductions in depressive symptoms compared to control conditions, according to a systematic review and meta-analysis of 12 randomized controlled trials with 711 participants. The pooled effect size was large (Hedges' g = –0.91), and effects appeared rapidly and remained consistent over several weeks. However, many studies had small sample sizes or risk of bias, and waitlist-controlled or crossover designs contributed heterogeneity. The review provides a living open data resource that will be updated as new evidence emerges.
medRxiv
August 7, 2025
Ben Deverett, Duan Li, Theresa R. Lii et al.
preprint
Ketamine produces dissociative, analgesic, and antidepressant effects, but it is unclear whether its underlying neurophysiological signatures can be separated. In this observational cohort study, 52 participants (healthy volunteers, elective surgery patients, and patients with depression) received a subanesthetic infusion of ketamine or placebo, with or without general anesthesia. When ketamine was given under general anesthesia, its characteristic low-frequency brain wave augmentation was absent, while high-frequency power modulation was preserved. This selective modulation suggests a method for investigating the distinct roles of high- and low-frequency neural activity in ketamine's behavioral effects.
medRxiv
July 29, 2025
Yuwen He, Shan Lei, Wangli Si et al.
preprint
Mindfulness meditation training alters functional connectivity in the somatomotor network (SMN) in both healthy and depressed populations. In 51 healthy and 35 depressed participants, common changes involved SMN-attentional network connections, suggesting that training modulates attention through somatic awareness. Population-specific changes also emerged: healthy individuals showed SMN-subcortical network shifts, indicating more pervasive effects on automatic processes, while depressed individuals showed SMN-default mode network interactions, which may explain why mindfulness is effective for depression. These altered connectivity patterns significantly predicted insomnia improvements after training in both groups, highlighting shared and distinct neural mechanisms underlying mindfulness-related mental health benefits.
medRxiv
July 29, 2025
Artemis Zavaliangos-Petropulu, Ginny Ghang, Toni Boltz et al.
preprint
Treatment-resistant depression affects 30-50% of people with major depressive disorder. Electroconvulsive therapy and ketamine can relieve it, but how they work is unclear. This transcriptome analysis of peripheral blood from 37 people receiving electroconvulsive therapy, 60 receiving ketamine, and 35 non-depressed controls found no longitudinal changes in gene expression for either treatment after correcting for multiple comparisons. In the ketamine group, one gene (IGKV1-9) differed between remitters and non-remitters at baseline. In the electroconvulsive therapy group, six co-regulated gene modules differed at baseline between patients and controls. Pre-treatment gene expression differences may have predictive value, but larger studies are needed.
medRxiv
June 18, 2025
Drummond E-Wen Mcculloch, K. M. Larsen, Annette Johansen et al.
preprint
Lysergic acid diethylamide (LSD) increases global cerebral blood flow and internal carotid artery flow without affecting artery diameter, effects opposite to those of psilocybin. Functional connectivity analyses show decreases in global connectivity (GCOR), which is negatively correlated with the increase in cerebral blood flow. An anticlockwise hysteresis loop between plasma drug levels and subjective effects suggests atypical pharmacodynamic mechanisms. These findings, derived from simultaneous PET-MRI in seven healthy volunteers, establish the dose-occupancy relation of LSD at cerebral serotonin 2A receptors and highlight neurophysiological differences from related psychedelics, providing insights for clinical development.
medRxiv
May 29, 2025
Michael Y. Wang, Neil W. Bailey, Paul B. Fitzgerald et al.
preprint
People with chronic pain who practice mindfulness react faster on attention tasks than those with chronic pain who do not meditate. In a study of 128 participants, those with chronic pain who meditated showed quicker reaction times on both a general attention test and a pain-related attention test compared to non-meditators with chronic pain. Non-meditators relied more on cues to alert their attention. However, no difference was found between the pain groups in attentional bias to pain-related words. The findings suggest mindfulness practice may help mitigate some attention difficulties linked to chronic pain.
medRxiv
February 21, 2025
Alene Sze Jing Yong, Sue E Brennan, Suzie Bratuskins et al.
preprint
Australia's Therapeutic Goods Administration rescheduled MDMA in July 2023, allowing its prescription for PTSD outside clinical trials. This manuscript outlines the development of an Australian Clinical Practice Guideline on MDMA-assisted psychotherapy for PTSD, using the GRADE process to weigh benefits and harms against other treatments. A multidisciplinary Guideline Development Group, supported by stakeholder and expert groups, will consider evidence certainty, patient values, resources, equity, acceptability, and feasibility. The guideline will be published on MAGICapp and in peer-reviewed outlets, with a companion guide for people with PTSD and their carers.
medRxiv
February 7, 2025
Andrew G. Breithaupt, Georges Naasan, Suzanne M. Shdo et al.
preprint
Psychosis is a common and burdensome symptom in neurodegenerative diseases. Analyzing 283 autopsy-confirmed cases, delusions were linked to atrophy in the right temporal lobe and bilateral frontal lobes, especially when persecutory or paranoid, implicating circuits for reward, emotion, self-awareness, and executive function. Misidentification delusions correlated with right ventral temporal-occipital atrophy, disrupting visual stream processing. No consistent atrophy patterns emerged with hallucinations. Damage to these brain regions predisposes individuals to delusions across different syndromes and pathologies, suggesting shared mechanisms between neurologic and psychiatric disorders.
medRxiv
October 13, 2024
Brian S. Barnett
preprint
A survey of researchers who published the most-cited psychedelics articles since 2000 found that federal grant applications for therapeutic psychedelic research at the National Institutes of Health (NIH) had a 16.7% funding rate, lower than the NIH's 23.4% average for R-01 equivalent grants from 1998 to 2023. No applications submitted before 2006–2010 were funded, but the rate since then (estimated at 19.05% to 22.2%) is close to the NIH's average annual rate of 20.6% for those years. Respondents believed the funding landscape has improved recently.
medRxiv
September 6, 2024
Hendrik-Jan De Vuyst, Angeliki-Ιlektra Karaiskou, Javier R. Soriano et al.
preprint
A single session of EEG-neurofeedback training can increase the occurrence of non-harmonic alpha-theta brainwave patterns during focused attention meditation, an effect that persists after training ends. Thirty participants received 25 minutes each of experimental training (auditory feedback when non-harmonic alpha-theta patterns were detected) and sham training (unrelated feedback). The increase in these brainwave patterns occurred across the whole scalp, not just at the training site, and was linked to improvements in depressive mood. People with higher depressive mood at the start showed stronger training effects. The findings suggest neurofeedback could help train brainwave patterns relevant to meditation, especially for those with depressive symptoms.